BioSpace News Archive

Timber Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, announced that it intends to offer and sell in an underwritten public offering, subject to market and other conditions, shares of its common stock.

Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, announced multiple scientific presentations at the American Academy of Optometry Annual Meeting 2021 being held in Boston, MA November 3 - 6, 2021.

Tarsus Pharmaceuticals, Inc., whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, announced that Bobak Azamian, M.D., Ph.D., President and Chief Executive Officer of Tarsus will present a corporate update at the Virtual Credit Suisse 30th Annual Healthcare Conference.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the establishment of its Cell Therapy Scientific Advisory Board (SAB).

Repare Therapeutics Inc. announced the closing on November 1, 2021 of its upsized underwritten public offering of 4,600,000 common shares at a public offering price of $22.00 per share, which included the exercise in full by the underwriters of their option to purchase up to 600,000 additional shares.

Ocugen, Inc. (NASDAQ: OCGN), today announced that it will host a conference call to discuss its third quarter 2021 financial results and provide a business update at 8:30 a.m. ET on Tuesday, November 9, 2021.

Teva Pharmaceutical Industries Ltd. announced that it successfully upsized and priced approximately $5,000,000,000 of its debut sustainability-linked senior notes.

Calysta, Inc. New scientific studies show shrimp welfare could be dramatically improved if fed Calysta’s FeedKind® protein, with the feed ingredient significantly reducing Early Mortality Syndrome risk.

Charge detection mass spectrometry adds new value to traditional mass spectrometry in detecting larger molecules such as coronaviruses.

In his recent opening address to the G20, Italian Prime Minister Mario Draghi highlighted vaccine inequity, emphasizing the fact that only 3% of eligible people living in the world’s poorest nations had received any form of COVID-19 vaccine, versus more than 70% in high-income countries.